
About Cellid
Cellid is a publicly listed company based in Seoul (South Korea) founded in 2014. Personalized vaccines for cancer and infectious diseases are developed. The company has 56 employees. Its focus areas include Life Sciences, Oncology, Drugs and Pan Cancer.
Company details
Cellid was founded in 2014 and is headquartered in Seoul, South Korea. Operations focus on the biotechnology sector, where a platform called CeliVax is utilized to activate the immune system against cancer cells. Personalized vaccines are being developed for cancer and infectious diseases. Pipeline candidates include BVAC-C, investigated for cervical, head, and neck cancers, and BVAC-B for gastric cancer, both in phase II clinical trials.
- Headquarters Seoul, South Korea
- Employees 56
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website cellid.co.kr
- Legal Name Cellid Co., Ltd.
- Annual Revenue$6.12 M (USD)112.28as on Dec 31, 2025
- Net Profit-$8.36 M (USD)1.55as on Dec 31, 2025
- EBITDA-$6.36 M (USD)3.64as on Dec 31, 2025
- InvestorsDSC Investment
& 4 more
- Employee Count56
Funding Insights of Cellid
- Total Rounds 4
- Investors Count 5
All 4 funding rounds of Cellid with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | Series A | β | β | ||
| Jun 2015 | Series A | β | DSC Investment, DAOL Investment | β | |
| Jun 2014 | Series A | β | β | ||
| Jun 2014 | Series A | β | β |
5 investors in total: 5 institutional.
Investors in Cellid
Cellid has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include DSC Investment, Green crosscell and Amicogen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and innovation services are provided by STIC Investments. | stic.co.kr | Seoul, South Korea | ||
Early-stage venture capital is invested primarily in South Korean startups. | 2012 | dscinvestment.com | Seoul, South Korea | |
Venture capital fund | daolinvestment.com | Seongnam-si, South Korea | ||
Enzymes and biotech solutions for pharma and industry are developed. | 2000 | amicogen.com | South Korea | |
Immunotherapy products and cryopreservation of cord blood | 1992 | greencrosscell.com | Seoul, South Korea |
Investor details for Cellid
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of Cellid
Cellid is a publicly listed company on the KRX with ticker symbol 299660 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Feb 2019
- Listed onKRX: 299660
- Listed entityCellid Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7299660001
- Share price2,310.00 KRW (+0.87% on the day) · 2026-10-14
- Market capitalisation67,561,818,180.00 KRW
- EPS (diluted, trailing year)-928.20 KRW
- Volume (last session)256,282
Financials of Cellid
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 8.84B KRW | -12.07B KRW | -9.19B KRW |
| 2024 | 4.17B KRW | -12.26B KRW | -9.54B KRW |
| 2023 | -11.61B KRW | -12.31B KRW | |
| 2022 | 480.0M KRW | -22.86B KRW | -12.31B KRW |
| 2021 | 909.1M KRW | -13.07B KRW | -19.40B KRW |
Detailed financial statements for Cellid
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Cellid
4 dated milestones of Cellid across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Cellid is founded.
- Funding First funding round.
- Funding Latest funding round, Series A,.
- IPO Lists on the stock exchange (IPO).
Web traffic of Cellid
The website of Cellid (cellid.co.kr) receives about 3.9K visits a month and ranks #3,891,169 among all websites worldwide, #4,942 in Biotechnology and Pharmaceuticals.
- Monthly visits3.9K
▼ 9.1% vs previous month
- Unique visitors1.7K
per month
- Global rank#3,891,169
among all websites
- Category rank#4,942
Health · Biotechnology and Pharmaceuticals
- Bounce rate32%
- Pages per visit2.1
- Average visit10 min 57 sec
- DevicesDesktop 27% Β· Mobile 73%
Websites whose visitors overlap most with Cellid. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
yakup.com | yakup.com | 100% | #118,603 | β | |
| pharmnews.com | 100% | #274,610 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cellid
Complete news archive for Cellid
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellid
Cellid was founded in 2014.
Cellid is headquartered in Seoul, South Korea.
Cellid has 56 employees.
Annual revenue of Cellid is $6.12M as on Dec 31, 2025.
Cellid was founded in 2014 and is headquartered in Seoul, South Korea. Operations focus on the biotechnology sector, where a platform called CeliVax is utilized to activate the immune system against cancer cells. Personalized vaccines are being developed for cancer and infectious diseases. Pipeline candidates include BVAC-C, investigated for cervical, head, and neck cancers, and BVAC-B for gastric cancer, both in phase II clinical trials.
Yes, Cellid is publicly traded on KRX under the ticker symbol 299660.
Cellid has 5 investors. Key investors include DSC Investment, Green crosscell, Amicogen, STIC Investments, and DAOL Investment.
